Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation

Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation

Background Diltiazem, a moderate cytochrome P450 3A4 isozyme/P‐glycoprotein inhibitor, may potentiate the bleeding risk of direct oral anticoagulants (DOACs) through pharmacokinetic interactions. We evaluated the association between concomitant use of diltiazem with DOACs and bleeding among patients...

Full description

Bibliographic Details
Main Authors: Yunwen Xu, Alex R. Chang, Lesley A. Inker, Mara McAdams‐DeMarco, Morgan E. Grams, Jung‐Im Shin
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
atrial fibrillation
chronic kidney disease
diltiazem
direct oral anticoagulants
drug–drug interactions
hemorrhage
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.122.025723

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.122.025723

Similar Items